Estradiol ( DrugBank: Estradiol )


7 diseases
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎5
46悪性関節リウマチ1
49全身性エリテマトーデス2
65原発性免疫不全症候群2
76下垂体性ゴナドトロピン分泌亢進症1
226間質性膀胱炎(ハンナ型)1
299嚢胞性線維症3

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04086225
(ClinicalTrials.gov)
January 17, 20199/9/2019Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).Relapsing Multiple Sclerosis (RMS)Drug: Cladribine;Drug: Placebo;Drug: Microgynon®Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNULLRecruiting18 Years45 YearsFemale34Phase 1Germany;Poland
2NCT03745144
(ClinicalTrials.gov)
January 17, 201914/11/2018Effects of Cladribine Tablets on the PK of Microgynon®A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With RMSRelapsing Multiple Sclerosis (RMS)Drug: Cladribine;Drug: Placebo;Drug: Microgynon®Merck KGaA, Darmstadt, GermanyNULLActive, not recruiting18 Years45 YearsFemale24Phase 1Germany;Poland
3EUCTR2014-005129-10-FI
(EUCTR)
27/01/201512/12/2014Multiple Sclerosis, menopause and hormone replacement therapyMultiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis Multiple sclerosis
MedDRA version: 17.1;Level: LLT;Classification code 10064137;Term: Progression of multiple sclerosis;System Organ Class: 100000004852
MedDRA version: 17.1;Classification code 10070425;Term: Multiple sclerosis exacerbation;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Femoston 2/10
Product Name: Femoston 2/10
INN or Proposed INN: ESTRADIOL HEMIHYDRATE
INN or Proposed INN: DYDROGESTERONE
Trade Name: Femoston 1/10
Product Name: Femoston 1/10
INN or Proposed INN: ESTRADIOL HEMIHYDRATE
INN or Proposed INN: DYDROGESTERONE
Irina ElovaaraNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
Finland
4EUCTR2006-005460-30-IT
(EUCTR)
22/05/200727/10/2008POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiolin Multiple sclerosis - POPART`MUSPOPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiolin Multiple sclerosis - POPART`MUS Multiple Sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis
Trade Name: DEMESTRIL SEPTEM
INN or Proposed INN: Estradiol
Trade Name: LUTENYL
INN or Proposed INN: Nomegestrol
OSPEDALI CIVILI DI LIONENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
300Italy
5NCT00127075
(ClinicalTrials.gov)
June 20054/8/2005POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple SclerosisPOPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple SclerosisMultiple SclerosisDrug: nomegestrol acetate;Drug: estradiol;Drug: placeboHospices Civils de LyonNULLActive, not recruiting18 Years50 YearsFemale300Phase 3France

46. 悪性関節リウマチ


臨床試験数 : 4,325 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03262740
(ClinicalTrials.gov)
September 11, 201724/8/2017The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsThe Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female SubjectsRheumatoid ArthritisDrug: BMS-986195;Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol)Bristol-Myers SquibbNULLCompleted18 Years40 YearsFemale58Phase 1United States

49. 全身性エリテマトーデス


臨床試験数 : 946 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03262727
(ClinicalTrials.gov)
September 1, 201724/8/2017The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsThe Effect of BMS-986165 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female SubjectsSystemic Lupus Erythematosus;Arthritic Psoriasis;Psoriasis;Inflammatory Bowel DiseasesDrug: BMS-986165;Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol)Bristol-Myers SquibbNULLCompleted18 Years40 YearsFemale49Phase 1United States
2NCT00006133
(ClinicalTrials.gov)
June 20003/8/2000Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: estradiol;Drug: ethinyl estradiol;Drug: medroxyprogesterone;Drug: norethindroneNational Center for Research Resources (NCRR)University of Alabama at BirminghamCompletedN/AN/AFemale970N/AUnited States

65. 原発性免疫不全症候群


臨床試験数 : 482 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01052623
(ClinicalTrials.gov)
January 201019/1/2010Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia TelangiectasiaAtaxia Telangiectasia;Growth FailureDrug: Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerateJohann Wolfgang Goethe University HospitalsNULLRecruiting3 Years18 YearsBoth24Phase 4Germany
2EUCTR2009-015739-34-DE
(EUCTR)
09/12/200914/09/2009Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT) - Growth hormone in AT (GHAT)Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT) - Growth hormone in AT (GHAT) This study will evaluate the status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and composition and neuroprotection in children with Ataxia telangiectasia (AT)Trade Name: Catapresan 75, Tabletten
INN or Proposed INN: Clonidinhydrochlorid
Trade Name: L-Arginin-hydrochlorid-einmolar Fresenius
INN or Proposed INN: Argininhydrochlorid
Trade Name: Progynova 21 mite
INN or Proposed INN: Estradiolvalerat
Trade Name: NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung
INN or Proposed INN: Somatotropin
Goethe-Universität Frankfurt/MainNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Germany

76. 下垂体性ゴナドトロピン分泌亢進症


臨床試験数 : 28 薬物数 : 46 - (DrugBank : 14) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 19
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100047299
2020-12-012021-06-12The use of morning urinary gonadotropins and sexual hormones in the diagnosis and monitoring treatment of central precocious pubertyThe use of morning urinary gonadotropins and sexual hormones in the diagnosis and monitoring treatment of central precocious puberty precocious pubertyGold Standard:gonadotropin releasing hormone stimulation test ;Index test:luteinizing hormone, follicle stimulating hormone, estradiol, prolactin, progesterone, testosterone, and human chorionic gonadotropin;The Children's Hospital, Zhejiang University School of MedicineNULLRecruiting310FemaleTarget condition:200;Difficult condition:100China

226. 間質性膀胱炎(ハンナ型)


臨床試験数 : 143 薬物数 : 171 - (DrugBank : 56) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 145
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03844412
(ClinicalTrials.gov)
November 4, 201915/2/2019Vestibulodynia: Understanding Pathophysiology and Determining Appropriate TreatmentsVestibulodynia: Understanding Pathophysiology and Determining Appropriate TreatmentsVestibulodynia;Temporomandibular Disorder;Fibromyalgia Syndrome;Irritable Bowel Syndrome;Migraines;Tension Headache;Endometriosis;Interstitial Cystitis;Back Pain;Chronic Fatigue SyndromeDrug: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream;Drug: Nortriptyline;Drug: Placebo cream;Drug: Placebo pillDuke UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Recruiting18 Years50 YearsFemale400Phase 2United States

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03724955
(ClinicalTrials.gov)
April 201929/10/2018Pilot E2 for Hypogonadal Women With CFBDPilot Study Evaluating the Effects of Estradiol for Hypogonadal Women With Cystic Fibrosis and OsteopeniaCystic Fibrosis Related Bone DiseaseDrug: Estradiol 2 mg;Other: PlaceboEmory UniversityNULLWithdrawn18 YearsN/AFemale0Phase 4United States
2NCT02144246
(ClinicalTrials.gov)
May 201419/5/2014Contraceptive Hormones and Women With Cystic FibrosisContraceptive Hormones and Women With Cystic Fibrosis: Satisfaction and Effects on DiseaseCystic Fibrosis Exacerbations While on and Off Hormonal ContraceptionOther: Non-hormonal period;Drug: Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mgUniversity of PennsylvaniaSociety of Family PlanningTerminated18 Years40 YearsFemale5Phase 1United States
3NCT02036879
(ClinicalTrials.gov)
February 201426/12/2013Gender Disparity and Hormones in Cystic FibrosisGender Disparity and Hormones in Cystic FibrosisCystic Fibrosis (CF)Drug: Loestrin (norethindrone acetate and ethinyl estradiol)University of Texas Southwestern Medical CenterNULLCompleted18 YearsN/AAll55Early Phase 1United States